{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:53:19Z","timestamp":1791139999955,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,5,24]],"date-time":"2010-05-24T00:00:00Z","timestamp":1274659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Platinating agents are used in the treatment of a spectrum of childhood cancers. Oxaliplatin, a third generation platinum compound, may provide less toxicity and be more effective. A phase 2 study was performed to estimate the response rate to single agent oxaliplatin in patients with refractory pediatric solid tumors, and to further describe the toxicities and pharmacokinetics of the drug in this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Subjects, \u226421 years of age at original diagnosis, received oxaliplatin (130\u2009mg\/m<jats:sup>2<\/jats:sup>) intravenously every 21 days. Prior platinum exposure was acceptable. Histologies included: Ewing sarcoma\/peripheral PNET, osteosarcoma, rhabdomyosarcoma, neuroblastoma, high and low grade astrocytoma, brain stem glioma, ependymoma, hepatoblastoma and selected rare tumors. A two\u2010stage design, enrolling 10\u2009+\u200910 subjects, was used for each disease stratum. Limited sampling pharmacokinetic studies were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 124 eligible subjects (75 males), 113 were evaluable for response and 69 (62%) had received platinum previously. Only one objective response was observed, a partial response in a 6\u2010year\u2010old child with ependymoma. An additional 13 subjects with various other solid tumors had stable disease, receiving a median (range) of 13.5 (2\u201317) cycles. Five subjects completed 17 treatment cycles. Thrombocytopenia was the most common toxicity observed. The median (range) terminal half\u2010life and clearance for ultrafiltrable platinum were 293 (187\u2013662\u2009hr) and 14.0 (1.9\u201324.9\u2009L\/hr\/m<jats:sup>2<\/jats:sup>), respectively (n\u2009=\u200949).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although reasonably well tolerated, oxaliplatin administered as a single agent has limited activity in pediatric patients with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2010;55:440\u2013445. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.22544","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T00:14:12Z","timestamp":1274919252000},"page":"440-445","source":"Crossref","is-referenced-by-count":48,"title":["A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study"],"prefix":"10.1002","volume":"55","author":[{"suffix":"III","given":"Orren","family":"Beaty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Blaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio","family":"Malogolowkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Krailo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Schaiquevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,19]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"6497","article-title":"Role of carrier ligand in platinum resistance in L1210 cells","volume":"50","author":"Gibbons GR","year":"1990","journal-title":"Cancer Res"},{"key":"e_1_2_6_3_2","first-page":"3500","article-title":"Enhanced replicative bypass of platinum\u2010DNA adducts in cisplatin\u2010resistant human ovarian carcinoma cell lines","volume":"54","author":"Mamenta EL","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00456a026"},{"key":"e_1_2_6_5_2","first-page":"4","article-title":"Oxaliplatin: Mechanism of action and antineoplastic activity","volume":"25","author":"Raymond E","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.54.5.770"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)81490-6"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.56.3.633"},{"key":"e_1_2_6_9_2","first-page":"799","article-title":"Role of carrier ligand in platinum resistance of human carcinoma cell lines","volume":"53","author":"Schmidt W","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005800520747"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00342-6"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(85)90102-8"},{"key":"e_1_2_6_13_2","first-page":"5970","article-title":"In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin","volume":"53","author":"Pendyala L","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00689042"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0753-3322(89)90004-8"},{"key":"e_1_2_6_16_2","first-page":"23","article-title":"Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer","volume":"25","author":"Becouarn Y","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008200825886"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(93)90073-O"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010489"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.136"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)03358-8"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.21.1608"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.2388"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.12.3159"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.551"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(00)00377-0"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/0-306-48523-0_7"},{"key":"e_1_2_6_30_2","volume-title":"Adapt II user's guide","author":"D'Argenio DZ","year":"1990"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90004-8"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.2307\/2531540"},{"key":"e_1_2_6_33_2","first-page":"193","article-title":"Immune\u2010mediated thrombocytopenia resulting from sensitivity to Oxaliplatin","volume":"81","author":"Kaliszewski J","year":"2006","journal-title":"Am J Hematol"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2739"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.126"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2006.01.001"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.056"},{"key":"e_1_2_6_38_2","first-page":"1205","article-title":"Clinical pharmacokinetics of oxaliplatin: A critical review","volume":"6","author":"Graham MA","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200311000-00007"},{"key":"e_1_2_6_40_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00280-002-0550-3","article-title":"Population pharmacokinetics of oxaliplatin","volume":"51","author":"Delord JP","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22241"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22544","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.22544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T12:22:04Z","timestamp":1700569324000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.22544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,19]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1002\/pbc.22544"],"URL":"https:\/\/doi.org\/10.1002\/pbc.22544","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,19]]}}}